COMMUNIQUÉS West-GlobeNewswire

Adial Pharmaceuticals CEO was a Featured Guest on The Big Biz Show
17/10/2025
GLEN ALLEN, Va., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. ( NASDAQ: ADIL ) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment [...]
WeightWatchers Launches RxFlexFund™, a New Employer Model for Expanding GLP-1 Coverage
17/10/2025
Provides a Differentiated Cost-Sharing Framework for GLP-1 Medications Paired With Clinical Oversight and Proven Behavior Change Support from WeightWatchers Clinic NEW YORK, Oct. 17, 2025 (GLOBE NEWSWIRE) -- WW [...]
Vera Therapeutics Announces ORIGIN 3 Late-Breaking Abstract Selected as Featured Oral Presentation at Opening Plenary Session of ASN Kidney Week 2025
17/10/2025
BRISBANE, Calif., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients [...]
Protext Mobility, Inc. (OTC: TXTM) Announces Plans for Corporate Website Redesign and Investor Relations Suite to Enhance Transparency and Shareholder Engagement
17/10/2025
NEW YORK, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Protext Mobility, Inc. (OTC: TXTM), an emerging leader in botanical-based biotechnology, today announced its strategic initiative to redesign its corporate website and develop [...]
Corvus Pharmaceuticals Announces Presentation of Interim Data from the Phase 1b/2 Clinical Trial of Ciforadenant for Patients with Metastatic Renal Cell Cancer at the European Society for Medical Oncology (ESMO) Congress 2025
17/10/2025
Trial is evaluating ciforadenant as a potential first line therapy for metastatic renal cell cancer (RCC) in combination with ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1) Interim data shows triplet therapy with [...]
ITM to Announce Phase 3 COMPETE Trial Post Hoc Subgroup Analyses and Host Satellite Symposium at NANETS 2025
17/10/2025
Garching / Munich, Germany, October 17, 2025 – ITM Isotope Technologies Munich SE (ITM) , a leading radiopharmaceutical biotech company, today announced that post hoc subgroup analyses data from its recent Phase 3 [...]
AKYNZEO® demonstrates superior prevention of chemotherapy-induced nausea and vomiting compared to the standard of care in patients receiving moderately emetogenic chemotherapy with additional predictive factors
17/10/2025
AKYNZEO ® demonstrates superior prevention of chemotherapy-induced nausea and vomiting compared to the standard of care in patients receiving moderately emetogenic chemotherapy with additional predictive factors Results [...]
TOLREMO therapeutics Completes First In Human Dose Escalation for TT125-802 and Presents Solid Tumor Monotherapy Results at ESMO 2025
17/10/2025
Monotherapy shows deep and durable responses in NSCLC and a best-in-class safety profile without thrombocytopenia Completion of monotherapy dose escalation part of the study will be followed by the start of combination [...]
CHMP recommends EU approval of Roche’s Gazyva/Gazyvaro for lupus nephritis
17/10/2025
Positive recommendation based on phase II NOBILITY and phase III REGENCY data showing Gazyva/Gazyvaro’s superiority over standard therapy alone 1,2 Gazyva/Gazyvaro is the only anti-CD20 antibody to demonstrate a [...]
Novartis Scemblix® receives positive CHMP opinion for the treatment of adults with newly diagnosed CML
17/10/2025
If approved, Scemblix will be indicated for adults with chronic myeloid leukemia (CML), both newly diagnosed and previously treated, expanding access to four times as many patients in Europe Scemblix is the only CML [...]
Chiesi Global Rare Diseases and Protalix Biotherapeutics Acknowledge CHMP Negative Opinion on Every Four Week Dosing Regimen of Elfabrio® (pegunigalsidase alfa) in the EU
17/10/2025
Every two weeks remains approved as a dosing regimen of Elfabrio in the EU PARMA, Italy and CARMIEL, Israel, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established [...]
Tilray Brands Marks Seven Years of Cannabis Legalization in Canada with the #1 Market-Leading Position by Revenue and Pioneering Brands with Growing Market Share in the World’s Largest Federally Legal Cannabis Market
17/10/2025
TORONTO, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray" or the "Company") (Nasdaq: TLRY; TSX: TLRY), a global lifestyle and consumer packaged goods company at the forefront of the global cannabis, [...]
Sight Sciences Announces Fee Schedule Establishment from Novitas Solutions and First Coast Service Options for the TearCare® Interventional Dry Eye Procedure
17/10/2025
MENLO PARK, Calif., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Sight Sciences , Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, [...]
Tonix Pharmaceuticals Presented Data on TNX-801 Mpox Vaccine at World Vaccine Congress–Europe 2025
17/10/2025
TNX-801 is a live virus vaccine investigational candidate, designed to provide durable protection against mpox and smallpox TNX-801 demonstrated favorable safety, immunogenicity, and long-term protection in multiple [...]
Eledon Pharmaceuticals to Present Results from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology Kidney Week 2025 Annual Meeting
17/10/2025
Conference call and webcast to discuss results to be held on November 7, 2025 at 8:00 a.m. ET IRVINE, Calif., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced an [...]
Climb Bio to Present Data at American Society of Nephrology (ASN) Kidney Week 2025
17/10/2025
Preclinical data for CLYM116, anti-APRIL monoclonal antibody, highlight favorable pharmacokinetic and pharmacodynamic profile, supporting development for IgA nephropathy (IgAN) Long-term follow-up clinical data for [...]
Communiqué de presse : Sanofi fournit une mise à jour de l’examen réglementaire du Rezurock dans l’UE pour le traitement de la maladie chronique du greffon contre l’hôte
17/10/2025
Sanofi fournit une mise à jour de l’examen réglementaire du Rezurock dans l’UE pour le traitement de la maladie chronique du greffon contre l’hôte Paris le 17 octobre 2025. Le Comité des médicaments à usage humain (CHMP [...]
Press Release: Sanofi provides update on regulatory review in the EU for Rezurock to treat chronic graft-vs-host disease
17/10/2025
Sanofi provides update on regulatory review in the EU for Rezurock to treat chronic graft-vs-host disease Paris, October 17, 2025. The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) [...]
AB Science annonce le succès d'un placement privé de 2,8 millions d'euros
17/10/2025
COMMUNIQUE DE PRESSE AB SCIENCE ANNONCE LE SUCCES D’UN PLACEMENT PRIVE D’ENVIRON 2,8 MILLIONS D’EUROS AB SCIENCE EST ENTIEREMENT FINANCEE POUR TERMINER LA PHASE 1 DE L'ETUDE AB8939 DANS LA LMA ET POUR EXECUTER UNE PHASE [...]

Pages